Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions

The market mechanism is less about the launch itself and more about whether Merck can prove it has a credible post-KEYTRUDA earnings bridge. If the oral PCSK9 asset gains formulary traction, the incremental value is not just another franchise line item; it improves MRK’s negotiating leverage with payers and reduces the stock’s terminal multiple discount tied to the 2028 cliff. The first-order upside is modest versus the company’s size, but the second-order effect is a lower perceived probability of a hard growth gap.

Competitive pressure is most relevant for Amgen and, to a lesser extent, Regeneron/Sanofi in lipids, where an oral therapy can attack the adherence advantage of injectables. That said, the key variable is not clinical novelty but reimbursement: LDL-lowering drugs often get trapped in prior auth, so peak sales assumptions can be too aggressive until real-world persistence and net pricing are visible. In oncology, FDA filing acceptance helps sentiment, but the value comes from de-risking pipeline breadth rather than near-term EPS.

Contrarian view: the consensus may be underpricing how long KEYTRUDA cash flows can remain resilient, which could make the equity response to pipeline news smaller than bulls expect. At the same time, the market may be overconfident in the cardiometabolic opportunity; if payer resistance mirrors prior PCSK9 launches, the product becomes an option, not a franchise. Watch for 1) formulary wins and net price commentary over the next 1-3 quarters, 2) clinical readouts/regulatory sequencing on the oncology filings over 6-12 months, and 3) any guidance language implying the company is truly offsetting 2028 rather than just buying time.